Cytotoxicity of the indole alkaloid reserpine from Rauwolfia serpentina against drug-resistant tumor cells

Phytomedicine

Volumn 22, Issue 2, 2015, Pages 308-318

  Abdelfatah, Sara A A ^a   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

ABC transporter; Cluster analysis; Collateral sensitivity; Molecular docking; Pharmacogenomics; Reserpine

Indexed keywords

ALKYLATING AGENT; BREAST CANCER RESISTANCE PROTEIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53; RESAZURIN; RESERPINE; SULFORHODAMINE B; TRANSCRIPTOME; VERAPAMIL; WNT PROTEIN; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; TP53 PROTEIN, HUMAN; TUMOR PROTEIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ADHESION; CELL MOTILITY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MICROARRAY ANALYSIS; MOLECULAR DOCKING; PRIORITY JOURNAL; RAUWOLFIA; SIGNAL TRANSDUCTION; WILD TYPE; WNT SIGNALING PATHWAY; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE INACTIVATION; GENETICS; METABOLISM; MULTIDRUG RESISTANCE; TUMOR CELL LINE;

RAUVOLFIA SERPENTINA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE KNOCKOUT TECHNIQUES; HUMANS; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; P-GLYCOPROTEINS; RAUWOLFIA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESERPINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922752787     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2015.01.002     Document Type: Article

References (61)

1. Akiyama S. et al. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog Mol. Pharmacol. 33 2 1988 144 147
2. Aller S.G. et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 323 5922 2009 1718 1722
3. Arceci R.J. Clinical significance of P-glycoprotein in multidrug resistance malignancies J. Amer. Soc. Hematol. 81 1993 2215 2222
4. Bakris G.L., Frohlich E.D. The evolution of antihypertensive therapy: An overview of four decades of experience J. Amer. College Cardiol. 14 7 1989 1595 1608
5. Beck W.T. et al. Effect of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine Biochem. Biophys. Res. Commun. 53 3 1988 959 966
6. Belkin M., Hardy W. Effect of reserpine Science 125 3241 1957 233 234
7. Bhat U.G., Winter M.A., Pearce H.L., Beck W.T. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line Mol. Pharmacol. 48 4 1995 682 689
8. Borra R.C. et al. A simple method to measure cell viability in proliferation and cytotoxicity assays Braz. Oral Res. 23 3 2009 255 262
9. Burton R. et al. Reticular activating system of brain stem and "animal hypnosis" antileukemic action of reserpine Science 125 3239 1956 156 157
10. Cantarella G, Di Benedetto G, Martinez G, Loreto C, Clementi G, Cantarella A, Prato A, Bernardini R Amylin prevents TRAIL-mediated apoptotic effects of reserpine in the rat gastric mucosa Peptides 30 8 2009 1466 1472
11. Chanprapaph K., Vachiramon V., Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: A review of cutaneous adverse events and management Dermatol. Res. Pract. 2014 2014 734249
12. Cheng J.-J., Tsai T.-H., Lin L.-C. New alkaloids and cytotoxic principles from Sinomenium acutum Planta Med. 78 17 2012 1873 1877
13. Doyle L.A., Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 47 2003 7340 7358
14. Efferth T. Personalized cancer medicine: From molecular diagnostics to targeted therapy with natural products Planta Med. 76 11 2010 1143 1154
15. Efferth T. et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs Clin. Cancer Res. 14 8 2008 2405 2412
16. Efferth T. Stem cells, cancer stem-like cells, and natural products Planta Med. 78 10 2012 935 942
17. Efferth T. The human ATP-binding cassette transporter genes: From the bench to the bedside Curr. Mol. Med. 1 1 2001 45 65
18. Efferth T., Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy Current Drug Targets 12 1 2011 122 132
19. Eichhorn T., Efferth T. P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs J. Ethnopharmacol. 141 2 2012 557 570
20. El-Deiry W.S. Role of oncogenes in resistance and killing by cancer therapeutic agents Curr. Opin. Oncol. 9 1 1997 79 87
21. El-Deiry W.S. The role of p53 in chemosensitivity and radiosensitivity Oncogene 22 47 2003 7486 7495
22. Evans A. et al. Glut-1 as a therapeutic target: Increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies Cancer Chemother. Pharmacol. 61 3 2008 377 393
23. Fagan V. et al. COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates Bioorg. Med. Chem. 20 10 2012 3223 3232
24. Gillet J.-P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes Biochim. Biophys. Acta 1775 2 2007 237 262
25. Gomez G.G. et al. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks Cancer Biol. Med. 10 4 2013 192 205
26. Hall M.D., Handley M.D., Gottesman M.M. Is resistance useless? Multidrug resistance and collateral sensitivity Trend. Pharmacol. Sci. 30 10 2009 546 556
27. Hetenyi C., Van Der Spoel D. Efficient docking of peptides to proteins without prior knowledge of the binding site Prot. Sci. 11 7 2002 1729 1737
28. Jetté L., Murphy G.F., Leclerc J.M., Beliveau R. Interaction of drugs with P-glycoprotein in brain capillaries Biochem. Pharmacol. 50 10 1995 1701 1709
29. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 455 1 1976 152 162
30. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics Brit. J. Cancer 26 4 1972 239 257
31. Kevekordes S. et al. SOS induction of selected naturally occurring substances in Escherichia coli (SOS chromotest) Mut. Res. 445 1 1999 81 91
32. Koch M. et al. Induction of pituitary tumours and hyperprolactinemia in female rats by estrogens. The effect of apomorphine, reserpine and L-dopa Arch. Toxicol 1980 89 91
33. Krishan A., Hamelik R.M. Flow cytometric monitoring of fluorescent drug retention and efflux Methods Mol. Med. 111 2005 149 166
34. Krusche B., Arend J., Efferth T. Synergistic inhibition of angiogenesis by artesunate and captopril in vitro; and in vivo Evid. Based Complement. Alternat. Med. 2013 2013 454783
35. Liao J. et al. New insights into p 53 functions through its target microRNAs J. Mol. Cell Biol. 6 3 2014 206 213
36. Luzina E.L., Popov A. V Synthesis, evaluation of anticancer activity and COMPARE analysis of N-bis(trifluoromethyl)alkyl-N'-substituted ureas with pharmacophoric moieties Euro. J. Med. Chem. 53 2012 364 373
37. Milne F.J., Pinkney-Atkinson V.J. Hypertension guideline 2003 update S. Afr. Med. J. 94 3 Pt 2 2004 220 225 pp. 209-16, 218
38. Nelson M., Nelson D.S., Hopper K.E. I. Tumor growth in mice with depressed capacity to mount inflammatory responses: Possible role of macrophages Amer. J. Pathol. 104 2 1981 114 124
39. Ohta R. et al. Ovariectomized mouse uterotrophic assay of 36 chemicals J. Toxicol. Sci. 37 5 2012 879 889
40. Panda S.K. et al. Phyto-pharmacognostical studies and quantitative determination of reserpine in different parts of Rauwolfia (spp.) of Eastern Odisha by UV spectroscopy Method Asian J. Plant Sci. Res. 2 2 2012 151 162
41. Paull K.D. et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm J. Natl. Cancer Inst. 81 1989 1088 1092
42. Pillay T. A comparison of two methods for measuring anti-hypertensive drug use: Concordance of use with South African standard treatment guidelines Bullet. World Health Organ. 87 6 2009 466 471
43. Qian X., Beck W.T. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines Amer. Assoc. Cancer Res. 50 1990 1132 1137
44. Reinhold W.C. et al. CellMiner: A web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set Cancer Res. 72 14 2012 3499 3511
45. Sarver J.G., Klis W.A., Byers J.P., Erhardt P.W. Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6 G accumulation in breast cancer cells that overexpress P-glycoprotein J. Biomol. Screen. 7 1 2002 29 34
46. Schlemmer S.R., Sirotnak F.M. Functional studies of P-glycoprotein in inside-out plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR 3. Properties and kinetics of the interaction of vinblastine with P-glycoprotein and evidence for its active mediated transport J. Biol. Chem. 269 49 1994 31059 31066
47. Seo E. et al. Antiangiogenic activity and pharmacogenomics of medicinal plants from traditional Korean medicine Evid. Based Complement. Alternat. Med. 2013 2013 131306
48. Tajima Y. et al. Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1 Phytomedicine 21 3 2014 323 332
49. Taylor T.E., Furnari F.B., Cavenee W.K. Targeting EGFR for treatment of gliboblastoma: Molecular basis to overcome resistance Curr. Cancer Drug Target. 12 3 2012 197 209
50. Tsutsui T. et al. Reserpine-induced cell transformation without detectable genetic effects in Syrian hamster embryo cells in culture Carcinogenesis 15 1 1994 11 14
51. Vasilyeva A. et al. Small molecule induction of MSH2-dependent cell death suggests a vital role of mismatch repair proteins in cell death DNA Rep. 8 1 2009 103 113
52. Villeneuve D.J., Parissenti A.M. The use of DNA microarrays to investigate the pharmacogenomics of drug response in living systems Curr. Topic. Med. Chem. 4 13 2004 1329 1345
53. Wahl O. et al. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products Curr. Med. Chem. 18 21 2011 3136 3155
54. Wakusawa S., Miyamoto K., Koshiura R. Increase of sensitivity and uptake of vinblastine by reserpine in rat ascites hepatoma Japan. J. Pharmacol. 36 2 1984 187 195
55. Wosikowski K. et al. Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells Biochim. Biophys. Acta 1497 2 2000 215 226
56. Wykosky J. et al. Therapeutic targeting of epidermal growth factor receptor in human cancer: Successes and limitations Chin. J. Cancer 30 1 2011 5 12
57. Yadav I.S. et al. Ensemble docking and molecular dynamics identify knoevenagel curcumin derivatives with potent anti-EGFR activity Gene 539 1 2014 82 90
58. Zamora J.M., Pearce H.L., Beck W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells Mol. Pharmacol. 33 4 1988 454 462
59. Zeeberg B.R. et al. RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis BMC Bioinform. 12 2011 52
60. Zeino M. et al. The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein - A well-known, yet poorly understood drug transporter Invest. New Drug 32 4 2014 618 625
61. Zihlif M. et al. Screening the antiangiogenic activity of medicinal plants grown and sold in Jordan Planta Med. 78 3 2012 297 301